| | FEBRUARY - 20239UTLOOKHealthcare Tech | | FEBRUARY - 20239UTLOOKHealthcare Tech their surface. As a final step, CAR T cells are infused back to the patient. After infusion, the number of CAR T cells in the patient's body is expected to increase further and with the help of designed receptors, they are expected to recognize and kill cancerous cells targeting the antigen on their surface."Is Remission Possible with CAR T Cell therapy?"Clinical trials of CAR T cell therapy began in the late nineties. As of 2009, this technology has reached its maximum level and CAR positive T cells have been included in clinical studies. THE FUTURE OF IMMUNOTHERAPY: CART CELLSPhase I and II trials are still evaluating the efficacy and safety of CAR T cells in hematological and solid cancers. CAR-T immunotherapy has also achieved remarkable results in the treatment of hematological malignancies and has led to the commercialization of CAR-T cells as pharmaceutical products. Despite the positive results, side effects such as loss of expression of the target antigen and cytokine release syndrome (CRS) need to be improved. In solid tumors, additional complications arising from intratumoral cell heterogeneity cause low responses and high toxicities.In Turkey, meeting the production efficiency and quality control criteria in the CAR T cell clinical study conducted by our team in leukemia and lymphoma patients was found to be satisfying for academic production. Response rates and toxicity profiles were agreeable for the previously heavily treated/refractory patient group. In the light of the results obtained, CAR T cells seem to be a safe and effective treatment option for CD19 expressing cancers. However, studies are underway to improve CAR technology to increase safety and efficacy, reduce production costs, and make it applicable beyond hematological cancers, and the number of clinical trials continues to increase exponentially.Advances in the Field of CAR-T Cell Therapy Have Been Exciting, to Say the Least...Clearly, there are challenges ahead that need to be adequately addressed. One of these challenges is a better understanding of the host tumor micro environment, particularly the immune response. Another challenge is making the therapy available for the treatment of many different human cancers, which will include testing new antigens and optimizing CARs to target specific cancers. Since CAR-T treatment is expensive and costly, it requires improvements in terms of pricing and affordability. But given the progress this therapy has made in recent years, we should be optimistic about its future development and utility.Summary...In the next decade, it is expected to enter a new era of cellular therapy in both hematological and solid cancer patients as a result of advances in genomic editing and production processes, as well as the development of additional strategies to manipulate the immune system. HTDespite all its success, immunotherapy still works for a certain period of time in a certain group of patients
< Page 8 | Page 10 >